Adinazolam-SR in panic disorder with agoraphobia: Relationship of daily dose to efficacy

Cameron S Carter, J. Fawcett, M. Hertzman, L. A. Papp, W. Jones, W. M. Patterson, R. P. Swinson, C. C. Weise, Richard J Maddock, A. Q. Denahan, M. Liebowitz

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: We report the results from a multicenter, double-blind, randomized, fixed-dose study designed to evaluate the relationship between daily dose and efficacy of adinazolam-SR in patients with panic disorder with agoraphobia. Method: Patients (N = 315) were randomized to one of four treatment groups (placebo, N = 83; 30-mg group, N = 79; 60-mg group, N = 81; and 90-mg group, N = 72) and then treated twice daily for 4 weeks. All treatment groups were comparable demographically. Primary efficacy measures included total number of panic attacks, global improvement score using the Clinical Global Impressions (CGI) scale, phobic anxiety dimension of the Symptom Checklist-90 phobic cluster, overall phobia state using the Phobia Scale, and severity of illness on the CGI. Results: The 60- and 90-mg/day adinazolam-SR treatment groups showed superior results when compared with the placebo group at Week 4 while the 30-mg group did not. Treatment with adinazolam-SR was well tolerated, with sedation the only treatment-emergent symptom that occurred more frequently in patients treated with adinazolam-SR than placebo. Conclusion: These results suggest that adinazolam-SR at doses of 60-mg/day or greater administered twice daily is a safe and effective treatment in selected patients with panic disorder with agoraphobia.

Original languageEnglish (US)
Pages (from-to)202-210
Number of pages9
JournalJournal of Clinical Psychiatry
Volume56
Issue number5
StatePublished - 1995
Externally publishedYes

Fingerprint

Agoraphobia
Panic Disorder
Phobic Disorders
Placebos
Therapeutics
Checklist
adinazolam
Anxiety

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Carter, C. S., Fawcett, J., Hertzman, M., Papp, L. A., Jones, W., Patterson, W. M., ... Liebowitz, M. (1995). Adinazolam-SR in panic disorder with agoraphobia: Relationship of daily dose to efficacy. Journal of Clinical Psychiatry, 56(5), 202-210.

Adinazolam-SR in panic disorder with agoraphobia : Relationship of daily dose to efficacy. / Carter, Cameron S; Fawcett, J.; Hertzman, M.; Papp, L. A.; Jones, W.; Patterson, W. M.; Swinson, R. P.; Weise, C. C.; Maddock, Richard J; Denahan, A. Q.; Liebowitz, M.

In: Journal of Clinical Psychiatry, Vol. 56, No. 5, 1995, p. 202-210.

Research output: Contribution to journalArticle

Carter, CS, Fawcett, J, Hertzman, M, Papp, LA, Jones, W, Patterson, WM, Swinson, RP, Weise, CC, Maddock, RJ, Denahan, AQ & Liebowitz, M 1995, 'Adinazolam-SR in panic disorder with agoraphobia: Relationship of daily dose to efficacy', Journal of Clinical Psychiatry, vol. 56, no. 5, pp. 202-210.
Carter CS, Fawcett J, Hertzman M, Papp LA, Jones W, Patterson WM et al. Adinazolam-SR in panic disorder with agoraphobia: Relationship of daily dose to efficacy. Journal of Clinical Psychiatry. 1995;56(5):202-210.
Carter, Cameron S ; Fawcett, J. ; Hertzman, M. ; Papp, L. A. ; Jones, W. ; Patterson, W. M. ; Swinson, R. P. ; Weise, C. C. ; Maddock, Richard J ; Denahan, A. Q. ; Liebowitz, M. / Adinazolam-SR in panic disorder with agoraphobia : Relationship of daily dose to efficacy. In: Journal of Clinical Psychiatry. 1995 ; Vol. 56, No. 5. pp. 202-210.
@article{b38b77e597904f4891fbd714731beebf,
title = "Adinazolam-SR in panic disorder with agoraphobia: Relationship of daily dose to efficacy",
abstract = "Background: We report the results from a multicenter, double-blind, randomized, fixed-dose study designed to evaluate the relationship between daily dose and efficacy of adinazolam-SR in patients with panic disorder with agoraphobia. Method: Patients (N = 315) were randomized to one of four treatment groups (placebo, N = 83; 30-mg group, N = 79; 60-mg group, N = 81; and 90-mg group, N = 72) and then treated twice daily for 4 weeks. All treatment groups were comparable demographically. Primary efficacy measures included total number of panic attacks, global improvement score using the Clinical Global Impressions (CGI) scale, phobic anxiety dimension of the Symptom Checklist-90 phobic cluster, overall phobia state using the Phobia Scale, and severity of illness on the CGI. Results: The 60- and 90-mg/day adinazolam-SR treatment groups showed superior results when compared with the placebo group at Week 4 while the 30-mg group did not. Treatment with adinazolam-SR was well tolerated, with sedation the only treatment-emergent symptom that occurred more frequently in patients treated with adinazolam-SR than placebo. Conclusion: These results suggest that adinazolam-SR at doses of 60-mg/day or greater administered twice daily is a safe and effective treatment in selected patients with panic disorder with agoraphobia.",
author = "Carter, {Cameron S} and J. Fawcett and M. Hertzman and Papp, {L. A.} and W. Jones and Patterson, {W. M.} and Swinson, {R. P.} and Weise, {C. C.} and Maddock, {Richard J} and Denahan, {A. Q.} and M. Liebowitz",
year = "1995",
language = "English (US)",
volume = "56",
pages = "202--210",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "5",

}

TY - JOUR

T1 - Adinazolam-SR in panic disorder with agoraphobia

T2 - Relationship of daily dose to efficacy

AU - Carter, Cameron S

AU - Fawcett, J.

AU - Hertzman, M.

AU - Papp, L. A.

AU - Jones, W.

AU - Patterson, W. M.

AU - Swinson, R. P.

AU - Weise, C. C.

AU - Maddock, Richard J

AU - Denahan, A. Q.

AU - Liebowitz, M.

PY - 1995

Y1 - 1995

N2 - Background: We report the results from a multicenter, double-blind, randomized, fixed-dose study designed to evaluate the relationship between daily dose and efficacy of adinazolam-SR in patients with panic disorder with agoraphobia. Method: Patients (N = 315) were randomized to one of four treatment groups (placebo, N = 83; 30-mg group, N = 79; 60-mg group, N = 81; and 90-mg group, N = 72) and then treated twice daily for 4 weeks. All treatment groups were comparable demographically. Primary efficacy measures included total number of panic attacks, global improvement score using the Clinical Global Impressions (CGI) scale, phobic anxiety dimension of the Symptom Checklist-90 phobic cluster, overall phobia state using the Phobia Scale, and severity of illness on the CGI. Results: The 60- and 90-mg/day adinazolam-SR treatment groups showed superior results when compared with the placebo group at Week 4 while the 30-mg group did not. Treatment with adinazolam-SR was well tolerated, with sedation the only treatment-emergent symptom that occurred more frequently in patients treated with adinazolam-SR than placebo. Conclusion: These results suggest that adinazolam-SR at doses of 60-mg/day or greater administered twice daily is a safe and effective treatment in selected patients with panic disorder with agoraphobia.

AB - Background: We report the results from a multicenter, double-blind, randomized, fixed-dose study designed to evaluate the relationship between daily dose and efficacy of adinazolam-SR in patients with panic disorder with agoraphobia. Method: Patients (N = 315) were randomized to one of four treatment groups (placebo, N = 83; 30-mg group, N = 79; 60-mg group, N = 81; and 90-mg group, N = 72) and then treated twice daily for 4 weeks. All treatment groups were comparable demographically. Primary efficacy measures included total number of panic attacks, global improvement score using the Clinical Global Impressions (CGI) scale, phobic anxiety dimension of the Symptom Checklist-90 phobic cluster, overall phobia state using the Phobia Scale, and severity of illness on the CGI. Results: The 60- and 90-mg/day adinazolam-SR treatment groups showed superior results when compared with the placebo group at Week 4 while the 30-mg group did not. Treatment with adinazolam-SR was well tolerated, with sedation the only treatment-emergent symptom that occurred more frequently in patients treated with adinazolam-SR than placebo. Conclusion: These results suggest that adinazolam-SR at doses of 60-mg/day or greater administered twice daily is a safe and effective treatment in selected patients with panic disorder with agoraphobia.

UR - http://www.scopus.com/inward/record.url?scp=0029074034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029074034&partnerID=8YFLogxK

M3 - Article

C2 - 7737960

AN - SCOPUS:0029074034

VL - 56

SP - 202

EP - 210

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 5

ER -